Therapeutic B-Cell Depletion Reverses Progression of Alzheimer’s Disease

Using three different murine transgenic models, scientists provide counterintuitive evidence that the Alzheimer’s disease progression required B cells.
[Nature Communications]
Kim, K., Wang, X., Ragonnaud, E., Bodogai, M., Illouz, T., DeLuca, M., McDevitt, R. A., Gusev, F., Okun, E., Rogaev, E., & Biragyn, A. (2021). Therapeutic B-cell depletion reverses progression of Alzheimer’s disease. Nature Communications, 12(1), 2185. https://doi.org/10.1038/s41467-021-22479-4 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Anti-CLL1 Chimeric Antigen Receptor T Cell Therapy in Children with Relapsed/Refractory Acute Myeloid Leukemia

Scientists tested the safety and efficacy of chimeric antigen receptor T cell therapy in refractory/relapsed acute myeloid leukemia .
[Clinical Cancer Research]
Zhang, H., Wang, P., Li, Z., He, Y., Gan, W., & Jiang, H. (2021). Anti-CLL1 chimeric antigen receptor T cell therapy in children with relapsed/refractory acute myeloid leukemia. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.CCR-20-4543 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Calcineurin Inhibitors Suppress Acute Graft-vs-Host Disease via NFAT-Independent Inhibition of T Cell Receptor Signaling

Researchers utilized T cells from mice that express LckS59A, which cannot accept a phosphate at residue 59, to initiate acute graft-versus-host disease.
[Journal of Clinical Investigation]
Otsuka, S., Melis, N., Gaida, M. M., Dutta, D., Weigert, R., & Ashwell, J. D. (2021). Calcineurin inhibitors suppress acute graft-vs-host disease via NFAT-independent inhibition of T cell receptor signaling. The Journal of Clinical Investigation. https://doi.org/10.1172/JCI147683 Cite
AbstractFull ArticleGraphical Abstract
Bookmark

No account yet? Register

0
Share

A Distal Foxp3 Enhancer Enables Interleukin-2 Dependent Thymic Treg Cell Lineage Commitment for Robust Immune Tolerance

The authors report that IL-2 – STAT5 signaling converged on an enhancer during Foxp3 induction.
[Immunity]
Dikiy, S., Li, J., Bai, L., Jiang, M., Janke, L., Zong, X., Hao, X., Hoyos, B., Wang, Z.-M., Xu, B., Fan, Y., Rudensky, A. Y., & Feng, Y. (2021). A distal Foxp3 enhancer enables interleukin-2 dependent thymic Treg cell lineage commitment for robust immune tolerance. Immunity, 0(0). https://doi.org/10.1016/j.immuni.2021.03.020 Cite
AbstractGraphical Abstract
Bookmark

No account yet? Register

0
Share

Integrative Bulk and Single-Cell Profiling of Pre-manufacture T-cell Populations Reveals Factors Mediating Long-Term Persistence of CAR T-cell Therapy

The authors extensively characterized the pre manufacture T-cells of 71 patients with B-cell malignancies on trial to receive anti-CD19 CAR T-cell therapy.
[Cancer Discovery]
Chen, G. M., Chen, C., Das, R. K., Gao, P., Chen, C.-H., Bandyopadhyay, S., Ding, Y.-Y., Uzun, Y., Yu, W., Zhu, Q., Myers, R. M., Grupp, S. A., Barrett, D. M., & Tan, K. (2021). Integrative bulk and single-cell profiling of pre-manufacture T-cell populations reveals factors mediating long-term persistence of CAR T-cell therapy. Cancer Discovery. https://doi.org/10.1158/2159-8290.CD-20-1677 Cite
Abstract
Bookmark

No account yet? Register

0
Share

A Selective HDAC8 Inhibitor Potentiates Antitumor Immunity and Efficacy of Immune Checkpoint Blockade in Hepatocellular Carcinoma

The authors demonstrated that selective HDAC8 inhibition elicited effective and durable responses to immune-checkpoint blockade by co-opting adaptive immunity through enhancer reprogramming.
[Science Translational Medicine]
Abstract
Bookmark

No account yet? Register

0
Share

Female Immunity Protects from Cutaneous Squamous Cell Carcinoma

Researchers presented data showing women presented less aggressive primary cutaneous squamous cell carcinoma and early strong immune activation.
[Clinical Cancer Research]
Abstract
Bookmark

No account yet? Register

0
Share

Epigenetic Reprogramming of Tumor Cell–Intrinsic STING Function Sculpts Antigenicity and T Cell Recognition of Melanoma

Scientists showed that promoter hypermethylation of cGAS and stimulator of interferon genes (STING) mediated their coordinated transcriptional silencing and contributed to the widespread impairment of the STING signaling function in clinically-relevant human melanomas and melanoma cell lines.
[Proceedings of the National Academy of Sciences of the United States of America]
Abstract
Bookmark

No account yet? Register

0
Share

Myeloid Cell–Derived HOCl Is a Paracrine Effector That Trans-inhibits IKK/NF-κB in Melanoma Cells and Limits Early Tumor Progression

Investigators revealed a role for myeloid-derived cells-derived hypochlorous acid (HOCl) as a small-molecule paracrine signaling factor that trans-inhibited inhibited IκB kinase (IKK) in melanoma tumor cells, mediating antitumor responses during early tumor progression.
[Science Signaling]
Abstract
Bookmark

No account yet? Register

0
Share

The Role of B Cells in PE Pathophysiology: A Potential Target for Perinatal Cell-Based Therapy?

The authors disscuss evidence on the ability of perinatal cells to inhibit B cell proliferation, impair B cell differentiation, and promote regulatory B cell formation.
[International Journal of Molecular Sciences]
Magatti, M., Masserdotti, A., Cargnoni, A., Papait, A., Stefani, F. R., Silini, A. R., & Parolini, O. (2021). The Role of B Cells in PE Pathophysiology: A Potential Target for Perinatal Cell-Based Therapy? International Journal of Molecular Sciences, 22(7), 3405. https://doi.org/10.3390/ijms22073405 Cite
Full Article
Bookmark

No account yet? Register

0
Share

City of Hope Enters Licensing Agreements with CytoImmune Therapeutics Inc. to Develop Portfolio of Chimeric Antigen Receptor-Natural Killer Therapies

City of Hope and CytoImmune Therapeutics Inc. have entered into worldwide exclusive license agreements to several patent applications related to methods to generate large numbers of fully functional natural killer (NK) cells derived from umbilical cord blood and compositions of chimeric receptors (CAR) for targeting NK cells to tumors.
[CytoImmune Therapeutics, Inc. (BusinessWire, Inc)]
Press Release
Bookmark

No account yet? Register

0
Share
Share